Merck’s RSV antibody treatment for infants is approved by FDA
The simplicity of Merck’s monoclonal antibody for RSV in infants could be a plus in its competition with AstraZeneca’s existing treatment.
Related Articles
FDA clears Moderna’s RSV vaccine for use in people aged 18 to 59
The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a welcome win.
BioNTech to buy CureVac in $1.25 billion deal, saying it will bolster cancer work
BioNTech said Thursday it would buy CureVac, its onetime competitor in the Covid-19 vaccine race, for about $1.25 billion in an all-stock transaction.
Russian Scientist Released After Four Months in Federal Custody
Kseniia Petrova, a Harvard researcher, still faces criminal charges for failing to declare scientific samples she was carrying in her suitcase.
Trump administration demands pharma companies begin drug price negotiations, a day after key deadline
Trump wants drug companies to bring their prices in line with what other countries pay.
Trump administration demands pharma companies begin drug price negotiations, a day after key deadline
Trump wants drug companies to bring their prices in line with what other countries pay.
Addiction experts grow restive as they wait for Kennedy to take action
Despite his compelling personal story of recovery from addiction, RFK Jr. has said much less about the U.S. drug crisis than other priorities like food…
Systematic reviews cited retracted articles, new study finds
A new study found some systematic reviews included retracted studies from paper mills, journals that produce low quality research
Exclusive: Kennedy’s new vaccine adviser was expert witness against Merck vaccine
One of the new vaccine advisers picked by U.S. Health Secretary Robert F. Kennedy Jr. has earned thousands of dollars as an expert witness in…
3 Pivotal Biopharma Growth Drivers Reshaping 2025 and Beyond | June 17 in Boston
Dive into top trends shaping the biopharma industry with STAT and experts, who will share practical insights and forward-looking signals. June 17 – Join us…
I study conflicts of interest. Here’s why RFK Jr’s approach to the vaccine advisory committee could backfire
Ridding the government, including CDC’s vaccine advisory committee, of industry interests should not play out this way, writes an expert on conflicts of interest.